0
0

Schizophrenia and Schizoaffective Disorder

text A A A

Sections

Excerpt

Ziprasidone is indicated for the acute treatment of schizophrenia and schizoaffective disorder. Its efficacy in the treatment of hospitalized patients with acute schizophrenia or schizoaffective disorder has been demonstrated in a series of double-blind, placebo-controlled trials of 4–6 weeks' duration (Daniel et al. 1999; Kane 2003; P. Keck et al. 1998; P. E. Keck et al. 2001). Additional randomized, double-blind, short-term (4- to 8-week) treatment studies using active antipsychotic agent comparators have indicated that ziprasidone has efficacy comparable to that of haloperidol, risperidone, and olanzapine for the treatment of positive symptoms and overall psychopathology (Addington et al. 2004; Goff et al. 1998; Simpson et al. 2004a). In a pooled analysis of four placebo-controlled, short-term trials and three active-comparator trials, Murray et al. (2004) demonstrated that ziprasidone dosages of at least 120 mg/day, in comparison with lower dosages, are associated with a more rapid and favorable response in overall psychopathology as well as a lower discontinuation rate due to inadequate clinical response, suggesting the importance of rapid titration to at least 120 mg/day in patients with acute schizophrenia (Kane 2003; McCue et al. 2006).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles
Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010;(6):CD005653.doi:10.1002/14651858.CD005653.pub2.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation